Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study
- Issued Date
- 2021
- Type
- Article
- Publisher
- LANCET ONCOLOGY
- Language
- 영어
- ISSN
- 1470-2045
- Citation Volume
- 22
- Citation Number
- 1
- Citation Start Page
- 85
- Citation End Page
- 97
- 파일 목록
-
-
관련 파일이 존재하지 않습니다.
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.